TrumpRx GLP-1 prices settle near $285 for Ozempic and $349 for Wegovy

The federal drug portal TrumpRx.gov listed Ozempic (semaglutide) at about $285 a month and Wegovy (semaglutide) at about $349 a month as of May 2026, according to pricing tracked by GLP-1 Cost Calculator ^[1]. Both drugs are made by Novo Nordisk and both fall under the most-favored-nation (MFN) pricing framework, which ties what US buyers pay to the lowest prices paid in comparable developed countries ^[1][2].

TrumpRx.gov launched February 5, 2026, and was expanded on May 18, 2026 ^[1][2]. As of that expansion, 17 manufacturers had signed agreements covering 86 percent of the branded drug market, and the GLP-1 class — including Ozempic, Wegovy, Mounjaro (tirzepatide) and Zepbound (tirzepatide) — was included ^[1].

The two accounts of the numbers do not match exactly

GLP-1 Cost Calculator lists a single point price for each drug: about $285 for Ozempic 1 mg and about $349 for Wegovy 2.4 mg, against retail prices it puts at roughly $900 and $1,350 a month ^[1]. The White House said in February that Ozempic and injectable Wegovy fall from $1,028 and $1,349 a month to "an average of $350 and as low as $199, depending on dosage," and that the Wegovy pill falls from $1,349 to as low as $149 ^[2]. The lower figures reflect dose-by-dose pricing; neither source publishes a full price list for every dose.

Zepbound (tirzepatide) is also covered. The White House said its monthly price falls from $1,088 to an average of $346 and as low as $299 ^[2]. GLP-1 Cost Calculator says per-unit pricing for Mounjaro and Zepbound was still being finalized as manufacturers complete their agreements as of May 2026 ^[1].

Who the program is aimed at

GLP-1 Cost Calculator says the portal is designed mainly for uninsured and underinsured patients and may not stack on top of Medicare, Medicaid or comprehensive employer coverage ^[1]. The White House described the audience as patients "who face high out-of-pocket costs for medications not fully covered by insurance" ^[2]. GLP-1 Cost Calculator describes a process of confirming eligibility on TrumpRx.gov, receiving a voucher or authorization code, and filling the prescription at a participating pharmacy listed by ZIP code ^[1].

Other savings routes are structured differently. Manufacturer savings cards can bring costs to $0 to $25 a month for commercially insured patients but cannot be used with Medicare or Medicaid, according to GLP-1 Cost Calculator, which also reports GoodRx typically brings Ozempic to $800 to $850 at major pharmacies and that compounded telehealth programs often start at $125 to $299 a month ^[1]. Novo Nordisk has announced roughly 50 percent list price reductions on Wegovy and Ozempic for 2027 ^[1].

Why it matters for patients

The difference between retail and TrumpRx pricing is large, but the price a patient actually pays varies by drug, dose, insurance status and state ^[1]. Someone whose employer plan already covers a GLP-1 injection at a low copay may find that coverage cheaper than the TrumpRx figure, while someone paying out of pocket may see the reverse ^[1].

A key open question is whether insurance can be used for TrumpRx purchases. The White House called on Congress to pass its "Great Healthcare Plan," which it said would codify the MFN savings and "enable coverage of TrumpRx.gov purchases under health plans" ^[2]. That legislation has not passed, so the practical effect of any interaction between insurance and portal pricing has not been established.

What happens next

The White House said additional manufacturers and medications would be added to TrumpRx.gov on a rolling basis, and that it is pursuing more MFN agreements ^[2]. It gave no timeline for the health care legislation it asked Congress to pass ^[2]. Novo Nordisk's roughly 50 percent list price reductions on Wegovy and Ozempic are announced for 2027 ^[1]. No target price or deadline for further GLP-1 cuts beyond that has been disclosed.